Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Danaher Corporation(DHR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for DHR
10/06/2026: DHR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Danaher Corporation is a diversified, highly-regarded life sciences and diagnostics company known for its operational discipline and recurring revenue model. By leveraging the Danaher Business System, the company has consistently built a leading position in bioprocessing and clinical diagnostics. Its primary growth story revolves around supporting advanced biopharmaceutical development and rapid, precise medical testing. While it has historically maintained high margins, investors should monitor risks related to biopharma R&D cycles, integration challenges from large acquisitions, and competition from other life science giants. The stock may best suit growth-oriented investors looking for exposure to high-quality healthcare infrastructure, though potential investors should weigh its premium valuation against future growth expectations.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Danaher consistently targets high-growth segments in life sciences and healthcare. |
| Momentum investor | Mixed fit | Momentum is conditional on positive market sentiment toward life science capital expenditures. |
| Value investor | Mixed fit | The company often trades at a premium valuation due to its quality and growth profile. |
| Dividend investor | Strong fit while signal remains positive | It offers a reliable, growing dividend, though current yields are modest. |
| Low-risk investor | Strong fit | The company's diversified, essential-product business model provides relative stability. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock can experience swings based on changes in bioprocessing demand. |
| Valuation risk | Medium / high | High P/E multiples require sustained earnings growth to justify current pricing. |
| Competition risk (Life Sciences giants) | Medium | Intense rivalry with TMO and others can pressure margins on key instruments. |
| Business quality | Strong | The Danaher Business System is a proven driver of operational efficiency and quality. |
| Dividend income | Low | This is primarily a growth-oriented stock rather than an income-heavy utility. |
| Execution risk | Medium | Large-scale M&A integration is always complex and carries inherent risks. |
Price Behavior
Flat / Range-Bound
The stock price has been trading within a narrow range with minimal directional movement.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -15.98% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 155.51B USD | Price to earnings Ratio 39.43 | 1Y Target Price 237.91 |
Price to earnings Ratio 39.43 | 1Y Target Price 237.91 | ||
Volume (30-day avg) 3.9M shares | Beta 0.8 | 52 Weeks Range 160.31 - 241.35 | Updated Date 10/06/2026 |
52 Weeks Range 160.31 - 241.35 | Updated Date 10/06/2026 | ||
Dividends yield (FY) 0.67% | Basic EPS (TTM) 5.61 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Biotechnology | Instruments, filters, and chromatography products for drug manufacturing. | The company sells the 'picks and shovels' for the drug development industry. |
| Diagnostics | Clinical analyzers and molecular testing kits for hospitals. | Steady revenue comes from daily medical testing and hospital needs. |
| Life Sciences | Advanced imaging and research tools for scientific discovery. | High-end research tools support innovation in academic and commercial labs. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 39.43 | Forward PE 23.81 | Enterprise Value 177.96B | Price to Sales(TTM) 6.19 |
Enterprise Value 177.96B | Price to Sales(TTM) 6.19 | ||
Enterprise Value to Revenue 7.09 | Enterprise Value to EBITDA 23.46 | Shares Outstanding 702.99M | Shares Floating 625.85M |
Shares Outstanding 702.99M | Shares Floating 625.85M | ||
Percent Insiders 10.96 | Percent Institutions 84.35 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Danaher Corporation
Exchange NYSE | Headquarters Washington, DC, United States | ||
IPO Launch date 1979-01-05 | CEO - | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 58000 | Website https://www.danaher.com |
Full time employees 58000 | Website https://www.danaher.com | ||
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.